Flow induces epithelial-mesenchymal transition, cellular heterogeneity and biomarker modulation in 3D ovarian cancer nodules
Open accessThe DOI matches its Crossref record; 99 of the 100 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Seventy-five percent of patients with epithelial ovarian cancer present with advanced-stage disease that is extensively disseminated intraperitoneally and prognosticates the poorest outcomes. Primarily metastatic within the abdominal cavity, ovarian carcinomas initially spread to adjacent organs by direct extension and then disseminate via the transcoelomic route to distant sites. Natural fluidic streams of malignant ascites triggered by physiological factors, including gravity and negative subdiaphragmatic pressure, carry metastatic cells throughout the peritoneum. We investigated the role of fluidic forces as modulators of metastatic cancer biology in a customizable microfluidic platform using 3D ovarian cancer nodules. Changes in the morphological, genetic, and protein profiles of biomarkers associated with aggressive disease were evaluated in the 3D cultures grown under controlled and continuous laminar flow. A modulation of biomarker expression and tumor morphology consistent with increased epithelial-mesenchymal transition, a critical step in metastatic progression and an indicator of aggressive disease, is observed because of hydrodynamic forces. The increase in epithelial-mesenchymal transition is driven in part by a posttranslational up-regulation of epidermal growth factor receptor (EGFR) expression and activation, which is associated with the worst prognosis in ovarian cancer. A flow-induced, transcriptionally regulated decrease in E-cadherin protein expression and a simultaneous increase in vimentin is observed, indicating increased metastatic potential. These findings demonstrate that fluidic streams induce a motile and aggressive tumor phenotype. The microfluidic platform developed here potentially provides a flow-informed framework complementary to conventional mechanism-based therapeutic strategies, with broad applicability to other lethal malignancies.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“| Ovarian (metastasis) | Rizvi et al. (2013) | Microfluidic chip with three channels | OVCAR-5 cells | Increased EMT, motility, and tumor aggressiveness |”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Rizvi et al., 2013
In the citing paper
“Interestingly, in comparison to static 3D cultures, the ovarian tumor nodules grown under flow exhibited morphological and phenotypical features indicative of increased EMT, such as an increase in epidermal growth factor receptor (EGFR) expression and activation, an increase in vimentin expression and the downregulation of E-cadherin expression.”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Rizvi et al., 2013
In the citing paper
“In particular, their microfluidic device enabled the formation of 3D micro-tumor nodules of OVCAR-5 cells on Matrigel under continuous flow.”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Rizvi et al., 2013
In the citing paper
“In order to better understand the physical and biological factors influencing ovarian cancer metastasis, Rizvi and colleagues developed a microfluidic platform that enables the investigation of fluidic forces as modulators for tumor metastasis (Rizvi et al., 2013).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Rizvi et al., 2013
In the citing paper
“Tissue-engineered 3D tumor models [100, 101], consisting of spheroids or organoids grown within synthetic ECM constructs, have enabled more rigorous tissue level studies of the TIME, and restore important architectural and stromal cues [102]”
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
A Perspective on Cancer Cell Metastasis
Chaffer, C. L., & Weinberg, R. A. (2011) · Science · doi:10.1126/science.1203543 · Cited by 4,807
Quantitative analysis of complex protein mixtures using isotope-coded affinity tags
Gygi, S. P., Rist, B., Gerber, S. A., Turecek, F., Gelb, M. H., & Aebersold, R. (1999) · Nature Biotechnology · doi:10.1038/13690 · Cited by 4,683
Cancer Metastasis: Building a Framework
Gupta, G. P., & Massagué, J. (2006) · Cell · doi:10.1016/j.cell.2006.11.001 · Cited by 4,247 · cited 4×
“The great majority of cancer cells that manage to colonize distant sites either persists as small colonies or suffers attrition over time (1, 6, 67, 68).”
BackgroundInfluentialTumor Metastasis: Molecular Insights and Evolving Paradigms
Valastyan, S., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.09.024 · Cited by 4,011 · cited 3×
“The great majority of cancer cells that manage to colonize distant sites either persists as small colonies or suffers attrition over time (1, 6, 67, 68).”
BackgroundDissemination and growth of cancer cells in metastatic sites
Chambers, A. F., Groom, A. C., & MacDonald, I. C. (2002) · Nature Reviews Cancer · doi:10.1038/nrc865 · Cited by 3,911 · cited 2×
“The great majority of cancer cells that manage to colonize distant sites either persists as small colonies or suffers attrition over time (1, 6, 67, 68).”
BackgroundIntegrins in cancer: biological implications and therapeutic opportunities
Desgrosellier, J. S., & Cheresh, D. A. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2748 · Cited by 3,736
Microenvironmental regulation of metastasis
Joyce, J. A., & Pollard, J. W. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2618 · Cited by 3,684 · cited 4×
“Curr Cancer Drug Targets 10(3):268–278.”
BackgroundInfluentialMetastasis: from dissemination to organ-specific colonization
Nguyen, D. X., Bos, P. D., & Massagué, J. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2622 · Cited by 2,649
Imaging and Photodynamic Therapy: Mechanisms, Monitoring, and Optimization
Celli, J. P., Spring, B. Q., Rizvi, I., Evans, C. L., Samkoe, K. S., Verma, S., Pogue, B. W., & Hasan, T. (2010) · Chemical Reviews · doi:10.1021/cr900300p · Cited by 2,324 · cited 3×
“A biophysical cytotoxic therapy that involves the light-based activation of a photosensitive molecule, PDT has demonstrated clinical promise for the treatment of peritoneal cancers, particularly ovarian carcinoma (90, 91).”
BackgroundSelf-citationIntegrated Genomic and Proteomic Analyses of a Systematically Perturbed Metabolic Network
Ideker, T., Thorsson, V., Ranish, J. A., Christmas, R., Buhler, J., Eng, J. K., Bumgarner, R., Goodlett, D. R., Aebersold, R., & Hood, L. (2001) · Science · doi:10.1126/science.292.5518.929 · Cited by 2,050
Debnath, J., Muthuswamy, S. K., & Brugge, J. S. (2003) · Methods · doi:10.1016/s1046-2023(03)00032-x · Cited by 1,995 · cited 2×
“This commercially available reconstituted basement membrane has been used by us and others to study the growth of 3D tumor nodules (51, 53, 55, 57, 59, 60, 75, 76), including ovarian cancer, and was a suitable stromal bed for the microfluidic chip used in the present study.”
MethodOvarian Cancer Development and Metastasis
Lengyel, E. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100105 · Cited by 1,672
Rethinking ovarian cancer: recommendations for improving outcomes
Vaughan, S., Coward, J. I., Bast, R. C., Berchuck, A., Berek, J. S., Brenton, J. D., Coukos, G., Crum, C. C., Drapkin, R., Etemadmoghadam, D., et al. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3144 · Cited by 1,464
Translational control in stress and apoptosis
Holcik, M., & Sonenberg, N. (2005) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1618 · Cited by 1,366
The biology of ovarian cancer: new opportunities for translation
Bast, R. C., Hennessy, B., & Mills, G. B. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2644 · Cited by 1,358 · cited 3×
“Dissemination to distant sites prognosticates the poorest outcomes for ovarian cancer patients and occurs via transcoelomic, lymphatic, or hematogenous routes (7, 9, 10).”
BackgroundThe physics of cancer: the role of physical interactions and mechanical forces in metastasis
Wirtz, D., Konstantopoulos, K., & Searson, P. C. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3080 · Cited by 1,344 · cited 1×
“(A) Ovarian cancer disseminates predominantly via movement of intraperitoneal fluid leading to a distinctive distribution pattern of tumor nodules (orange) involving four common abdomino-pelvic sites: (1) cul-de-sac (peritoneal fold between the rectum and the posterior wall of the uterus); (2) right infracolic space (…”
BackgroundThree-dimensional culture models of normal and malignant breast epithelial cells
Lee, G. Y., Kenny, P. A., Lee, E. H., & Bissell, M. J. (2007) · Nature Methods · doi:10.1038/nmeth1015 · Cited by 1,336 · cited 2×
“This commercially available reconstituted basement membrane has been used by us and others to study the growth of 3D tumor nodules (51, 53, 55, 57, 59, 60, 75, 76), including ovarian cancer, and was a suitable stromal bed for the microfluidic chip used in the present study.”
MethodNelson, C. M., & Bissell, M. J. (2006) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.22.010305.104315 · Cited by 1,130 · cited 2×
“This commercially available reconstituted basement membrane has been used by us and others to study the growth of 3D tumor nodules (51, 53, 55, 57, 59, 60, 75, 76), including ovarian cancer, and was a suitable stromal bed for the microfluidic chip used in the present study.”
MethodPetersen, O. W., Rønnov-Jessen, L., Howlett, A. R., & Bissell, M. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.19.9064 · Cited by 1,094 · cited 2×
“This commercially available reconstituted basement membrane has been used by us and others to study the growth of 3D tumor nodules (51, 53, 55, 57, 59, 60, 75, 76), including ovarian cancer, and was a suitable stromal bed for the microfluidic chip used in the present study.”
MethodKenny, P. A., Lee, G. Y., Myers, C. A., Neve, R. M., Semeiks, J. R., Spellman, P. T., Lorenz, K., Lee, E. H., Barcellos‐Hoff, M. H., PETERSEN, O. W., et al. (2008) · eScholarship (California Digital Library) · Cited by 1,039
The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy
Chu, I. M., Hengst, L., & Slingerland, J. M. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2347 · Cited by 990 · cited 1×
“The cell-cycle regulator p27Kip1 modulates proliferation, motility, and apoptosis by inhibiting an array of cyclindependent kinases including cell-division control protein kinase 2 (CDC2) and also plays a role in cytoskeletal remodeling (38, 39).”
BackgroundEpithelial-mesenchymal transition in cancer development and its clinical significance
Iwatsuki, M., Mimori, K., Yokobori, T., Ishi, H., Beppu, T., Nakamori, S., Baba, H., & Mori, M. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2009.01419.x · Cited by 780
Debnath, J., Mills, K. R., Collins, N. L., Reginato, M. J., Muthuswamy, S. K., & Brugge, J. S. (2002) · Cell · doi:10.1016/s0092-8674(02)01001-2 · Cited by 763
Feedback regulation of EGFR signalling: decision making by early and delayed loops
Avraham, R., & Yarden, Y. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3048 · Cited by 672
Thomson, S., Buck, E., Petti, F., Griffin, G., Brown, E., Ramnarine, N., Iwata, K. K., Gibson, N., & Haley, J. D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1058 · Cited by 663 · cited 1×
“(34), non–smallcell lung carcinoma cells were differentially sensitive to the EGFR inhibitor erlotinib, and EMT status was a key determinant of sensitivity to treatment.”
BackgroundModeling tissue-specific signaling and organ function in three dimensions
Schmeichel, K. L., & Bissell, M. J. (2003) · Journal of Cell Science · doi:10.1242/jcs.00503 · Cited by 585
ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini
Muthuswamy, S. K., Li, D., Lelievre, S., Bissell, M. J., & Brugge, J. S. (2001) · Nature Cell Biology · doi:10.1038/ncb0901-785 · Cited by 554 · cited 2×
“This commercially available reconstituted basement membrane has been used by us and others to study the growth of 3D tumor nodules (51, 53, 55, 57, 59, 60, 75, 76), including ovarian cancer, and was a suitable stromal bed for the microfluidic chip used in the present study.”
MethodShields, J. D., Fleury, M. E., Yong, C., Tomei, A. A., Randolph, G. J., & Swartz, M. A. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.04.020 · Cited by 552 · cited 1×
“(48) have shown that interstitial flow enhances the migratory potential of metastatic cancer cells.”
BackgroundOvarian Cancer Metastasis: Integrating insights from disparate model organisms
Naora, H., & Montell, D. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1611 · Cited by 538 · cited 2×
“Dissemination to distant sites prognosticates the poorest outcomes for ovarian cancer patients and occurs via transcoelomic, lymphatic, or hematogenous routes (7, 9, 10).”
BackgroundMechanisms of transcoelomic metastasis in ovarian cancer
Tan, D. S., Agarwal, R., & Kaye, S. B. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70939-1 · Cited by 520 · cited 5×
“Dissemination to distant sites prognosticates the poorest outcomes for ovarian cancer patients and occurs via transcoelomic, lymphatic, or hematogenous routes (7, 9, 10).”
BackgroundInfluentialInterstitial flow influences direction of tumor cell migration through competing mechanisms
Polacheck, W. J., Charest, J. L., & Kamm, R. D. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1103581108 · Cited by 509 · cited 1×
“(49) demonstrated that the directionality of tumor cell migration depends on the flow strength and cell density in collagen I scaffolds.”
BackgroundNishizuka, S., Charboneau, L., Young, L., Major, S., Reinhold, W. C., Waltham, M., Kouros-Mehr, H., Bussey, K. J., Lee, J. K., Espina, V., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2331323100 · Cited by 474
Integrins as therapeutic targets: lessons and opportunities
Cox, D., Brennan, M., & Moran, N. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3266 · Cited by 456
Rajasekhar, V. K., Viale, A., Socci, N. D., Wiedmann, M., Hu, X., & Holland, E. C. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00395-2 · Cited by 420
Haslehurst, A. M., Koti, M., Dharsee, M., Nuin, P., Evans, K., Geraci, J., Childs, T., Chen, J., Li, J., Weberpals, J., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-91 · Cited by 402 · cited 1×
“(33) showed that modulation of key regulators of EMT contributed directly to cisplatin resistance in ovarian cancer cells and primary tumors.”
BackgroundCaswell, P. T., Chan, M., Lindsay, A. J., McCaffrey, M. W., Boettiger, D., & Norman, J. C. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200804140 · Cited by 388
Loss of E-Cadherin Promotes Ovarian Cancer Metastasis via α5-Integrin, which Is a Therapeutic Target
Sawada, K., Mitra, A. K., Radjabi, A. R., Bhaskar, V., Kistner, E. O., Tretiakova, M., Jagadeeswaran, S., Montag, A., Becker, A., Kenny, H. A., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5167 · Cited by 356 · cited 1×
“(2) The resultant increase in EGFR signaling modulates molecular pathways (26, 27) that induce a transcriptionally regulated decrease in (3) E-cadherin protein expression.”
BackgroundXu, F., Celli, J., Rizvi, I., Moon, S., Hasan, T., & Demirci, U. (2011) · Biotechnology Journal · doi:10.1002/biot.201000340 · Cited by 337
Self-citationCelis, J. E., Kruhøffer, M., Gromova, I., Frederiksen, C., Østergaard, M., Thykjaer, T., Gromov, P., Yu, J., Pálsdóttir, H., Magnusson, N., et al. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)01771-3 · Cited by 314
Vimentin contributes to human mammary epithelial cell migration
Gilles, C., Polette, M., Zahm, J.-M., Tournier, J.-M., Volders, L., Foidart, J.-M., & Birembaut, P. (1999) · Journal of Cell Science · doi:10.1242/jcs.112.24.4615 · Cited by 314
CROSS, S. S. (1997) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199705)182:1<1::aid-path808>3.0.co;2-b · Cited by 307
Tissue structure, nuclear organization, and gene expression in normal and malignant breast.
Bissell, M. J., Weaver, V. M., Lelièvre, S. A., Wang, F., Petersen, O. W., & Schmeichel, K. L. (1999) · PubMed · Cited by 297
Tamimi, A., Rinker, E. B., & Sandall, O. C. (1994) · Journal of Chemical & Engineering Data · doi:10.1021/je00014a031 · Cited by 280 · cited 1×
“We assumed that the diffusion coefficient of CO2 in medium can be approximated as the diffusion coefficient of CO2 in water, which was reported as 2 × 10 m(2)/s (96).”
Adhesion molecule signalling: not always a sticky business
Cavallaro, U., & Dejana, E. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3068 · Cited by 277 · cited 1×
“EGFR activation has been shown to down-regulate E-cadherin (26–28), a transmembrane glycoprotein involved in intercellular adhesions mediated by a protein complex that includes β-catenin (29).”
BackgroundBurleson, K. M., Casey, R. C., Skubitz, K. M., Pambuccian, S. E., Oegema, T. R., & Skubitz, A. P. N. (2004) · Gynecologic Oncology · doi:10.1016/j.ygyno.2003.12.034 · Cited by 269
Kenny, H. A., Krausz, T., Yamada, S. D., & Lengyel, E. (2007) · International Journal of Cancer · doi:10.1002/ijc.22874 · Cited by 243
Ahmed, N., Thompson, E. W., & Quinn, M. A. (2007) · Journal of Cellular Physiology · doi:10.1002/jcp.21240 · Cited by 237
Ahmed, N., Abubaker, K., Findlay, J., & Quinn, M. (2010) · Current Cancer Drug Targets · doi:10.2174/156800910791190175 · Cited by 234
Intraperitoneal cancer dissemination: Mechanisms of the patterns of spread
Carmignani, C. P., Sugarbaker, T. A., Bromley, C. M., & Sugarbaker, P. H. (2003) · Cancer and Metastasis Reviews · doi:10.1023/a:1023791229361 · Cited by 232
The morphological and molecular features of the epithelial-to-mesenchymal transition
Moreno-Bueno, G., Peinado, H., Molina, P., Olmeda, D., Cubillo, E., Santos, V., Palacios, J., Portillo, F., & Cano, A. (2009) · Nature Protocols · doi:10.1038/nprot.2009.152 · Cited by 221
Malignant ascites: past, present, and future
Adam, R. A., & Adam, Y. G. (2004) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2004.01.035 · Cited by 209 · cited 2×
“The abnormal buildup of protein- and cell-rich ascitic fluid in the peritoneal cavity occurs frequently in ovarian cancer and is associated with a dismal quality of life and a grim median survival (7, 11).”
BackgroundAhmed, N., Maines-Bandiera, S., Quinn, M. A., Unger, W. G., Dedhar, S., & Auersperg, N. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00478.2005 · Cited by 207
Tumor cell cycle arrest induced by shear stress: Roles of integrins and Smad
Chang, S.-F., Chang, C. A., Lee, D.-Y., Lee, P.-L., Yeh, Y.-M., Yeh, C.-R., Cheng, C.-K., Chien, S., & Chiu, J.-J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712353105 · Cited by 201 · cited 1×
“(50) have shown that flow-induced shear stress causes cell-cycle arrest in monolayer cultures of multiple cancer cell lines.”
BackgroundRizvi, I., Celli, J. P., Evans, C. L., Abu-Yousif, A. O., Muzikansky, A., Pogue, B. W., Finkelstein, D., & Hasan, T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1783 · Cited by 191 · cited 5×
“The protocols for nonflow 3D ovarian cancer cultures were based on previously published methods developed by us and others (51, 53, 55, 57, 59, 60, 75, 76).”
BackgroundMethodInfluentialSelf-citationRegulation of the cytoskeleton: an oncogenic function for cdk inhibitors?
Besson, A., Assoian, R. K., & Roberts, J. M. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1501 · Cited by 189 · cited 1×
“The cell-cycle regulator p27Kip1 modulates proliferation, motility, and apoptosis by inhibiting an array of cyclindependent kinases including cell-division control protein kinase 2 (CDC2) and also plays a role in cytoskeletal remodeling (38, 39).”
BackgroundCowden Dahl, K. D., Symowicz, J., Ning, Y., Gutierrez, E., Fishman, D. A., Adley, B. P., Stack, M. S., & Hudson, L. G. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5046 · Cited by 182 · cited 1×
“(2) The resultant increase in EGFR signaling modulates molecular pathways (26, 27) that induce a transcriptionally regulated decrease in (3) E-cadherin protein expression.”
BackgroundSugarbaker, P. H. (1996) · Cancer Treatment and Research · doi:10.1007/978-1-4613-1247-5_6 · Cited by 181
Combination of Photodynamic Therapy with Anti-Cancer Agents
Zuluaga, M.-F., & Lange, N. (2008) · Current Medicinal Chemistry · doi:10.2174/092986708784872401 · Cited by 163 · cited 1×
“PDT synergizes with chemotherapeutics and biological agents (19, 60, 89, 92), and these combinations are in early clinical trials.”
BackgroundCarmen, M. G. D., Rizvi, I., Chang, Y., Moor, A. C. E., Oliva, E., Sherwood, M. E., Pogue, B. W., & Hasan, T. G. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji314 · Cited by 160
Self-citationEpidermal Growth Factor Receptor Signaling and the Invasive Phenotype of Ovarian Carcinoma Cells
Alper, Ö., Bergmann‐Leitner, E. S., Bennett, T. A., Hacker, N. F., Stromberg, K., & Stetler‐Stevenson, W. G. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.18.1375 · Cited by 158
Psyrri, A., Kassar, M., Yu, Z., Bamias, A., Weinberger, P. M., Markakis, S., Kowalski, D., Camp, R. L., Rimm, D. L., & Dimopoulos, M. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1436 · Cited by 150 · cited 2×
“Several studies have identified the EGFR as an independent prognostic indicator for poor outcomes (20, 80), although the clinical consequences of EGFR expression remain controversial (23, 24, 81).”
BackgroundMethodMMP-2 functions as an early response protein in ovarian cancer metastasis
Kenny, H. A., & Lengyel, E. (2009) · Cell Cycle · doi:10.4161/cc.8.5.7703 · Cited by 149
Disaggregation and invasion of ovarian carcinoma ascites spheroids
Burleson, K. M., Boente, M. P., Pambuccian, S. E., & Skubitz, A. P. (2006) · Journal of Translational Medicine · doi:10.1186/1479-5876-4-6 · Cited by 146
Posadas, E. M., Liel, M. S., Kwitkowski, V., Minasian, L., Godwin, A. K., Hussain, M. M., Espina, V., Wood, B. J., Steinberg, S. M., & Kohn, E. C. (2007) · Cancer · doi:10.1002/cncr.22545 · Cited by 143 · cited 1×
“Several studies have identified the EGFR as an independent prognostic indicator for poor outcomes (20, 80), although the clinical consequences of EGFR expression remain controversial (23, 24, 81).”
BackgroundMeirelles, K., Benedict, L. A., Dombkowski, D., Pépin, D., Preffer, F. I., Teixeira, J. M., Tanwar, P. S., Young, R. H., MacLaughlin, D. T., Donahoe, P. K., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120733109 · Cited by 135 · cited 2×
“(88) to predict increased colony formation, shorter tumor-free intervals in vivo, and not only resistance but stimulation by doxorubicin.”
BackgroundSeiden, M. V., Burris, H. A., Matulonis, U. A., Hall, J. B., Armstrong, D. K., Speyer, J. L., Weber, J., & Muggia, F. M. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.10.019 · Cited by 134 · cited 2×
“Several studies have identified the EGFR as an independent prognostic indicator for poor outcomes (20, 80), although the clinical consequences of EGFR expression remain controversial (23, 24, 81).”
BackgroundThe role of lymphatic obstruction in the formation of ascites in a murine ovarian carcinoma.
Feldman, G. B., KNAPP, R. C., Order, S. E., & Hellmän, S. (1972) · PubMed · Cited by 133
Multi-step microfluidic device for studying cancer metastasis
Chaw, K. C., Manimaran, M., Tay, E. H., & Swaminathan, S. (2007) · Lab on a Chip · doi:10.1039/b707399m · Cited by 127 · cited 1×
“Microfluidic systems also have been used to mimic intravasation and extravasation to study cancer metastasis (69, 70).”
MethodPhase II Trial of Debulking Surgery and Photodynamic Therapy for Disseminated Intraperitoneal Tumors
Hendren, S. K., Hahn, S. M., Spitz, F. R., Bauer, T. W., Rubin, S. C., Zhu, T. C., GLATSTEIN, E. J., & Fraker, D. L. (2001) · Annals of Surgical Oncology · doi:10.1007/s10434-001-0065-x · Cited by 122 · cited 1×
“A biophysical cytotoxic therapy that involves the light-based activation of a photosensitive molecule, PDT has demonstrated clinical promise for the treatment of peritoneal cancers, particularly ovarian carcinoma (90, 91).”
BackgroundManipulating biological agents and cells in micro-scale volumes for applications in medicine
Tasoglu, S., Gurkan, U. A., Wang, S., & Demirci, U. (2013) · Chemical Society Reviews · doi:10.1039/c3cs60042d · Cited by 109 · cited 1×
“The channel inlet and outlet regions were fabricated with a 127° angle to facilitate fluid entrance to and exit from the channels (93, 94).”
MethodSelf-citationPostgenomic global analysis of translational control induced by oncogenic signaling
Rajasekhar, V. K., & Holland, E. C. (2004) · Oncogene · doi:10.1038/sj.onc.1207546 · Cited by 102
Louie, K. G., Hamilton, T. C., Winker, M. A., Behrens, B. C., Tsuruo, T., Klecker, R. W., McKoy, Grotzinger, K. R., Myers, C. E., Young, R. C., et al. (1986) · Biochemical Pharmacology · doi:10.1016/0006-2952(86)90221-2 · Cited by 100 · cited 2×
“EpithelialovariancancerNIH:OVCAR5cellswereobtained from Thomas Hamilton (Fox Chase Cancer Institute, Philadelphia, PA) (95).”
MethodOhmori, T., Yang, J.-L., Price, J. O., & Arteaga, C. L. (1998) · Experimental Cell Research · doi:10.1006/excr.1998.4261 · Cited by 98
Moon, S., Gurkan, U. A., Blander, J., Fawzi, W. W., Aboud, S., Mugusi, F. M., Kuritzkes, D. R., & Demirci, U. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021409 · Cited by 98 · cited 1×
“The channel inlet and outlet regions were fabricated with a 127° angle to facilitate fluid entrance to and exit from the channels (93, 94).”
MethodSelf-citationIntegrating cancer genomics and proteomics in the post-genome era
Hanash, S., Bobek, M. P., Rickman, D. S., Williams, T., Rouillard, J. M., Kuick, R. D., & Puravs, E. (2002) · PROTEOMICS · doi:10.1002/1615-9861(200201)2:1<69::aid-prot69>3.0.co;2-8 · Cited by 98
The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer
Gui, T., & Shen, K. (2012) · Cancer Epidemiology · doi:10.1016/j.canep.2012.06.005 · Cited by 94 · cited 2×
“Nonetheless, the EGFR remains an important and relevant focus for molecularly targeted therapies, as evidenced by recent clinical trials (23, 80, 82, 83).”
BackgroundShin, M. K., Kim, S. K., & Jung, H. (2011) · Lab on a Chip · doi:10.1039/c1lc20671k · Cited by 94 · cited 1×
“Microfluidic systems also have been used to mimic intravasation and extravasation to study cancer metastasis (69, 70).”
MethodThe CATH protein family database: A resource for structural and functional annotation of genomes
Orengo, C. A., Bray, J. E., Buchan, D. W. A., Harrison, A., Lee, D., Pearl, F. M. G., Sillitoe, I., Todd, A. E., & Thornton, J. M. (2002) · PROTEOMICS · doi:10.1002/1615-9861(200201)2:1<11::aid-prot11>3.0.co;2-t · Cited by 93
Runnels, J. M., Chen, N., Ortel, B. J., Kato, D. T., & Hasan, T. G. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690448 · Cited by 92
Self-citationHolz, C., Niehr, F., Boyko, M. M., Hristozova, T., Distel, L. V., Budach, V., & Tinhofer, I. (2011) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2011.05.042 · Cited by 91
Ki-67 as a Molecular Target for Therapy in an In vitro Three-Dimensional Model for Ovarian Cancer
Rahmanzadeh, R., Rai, P., Celli, J. P., Rizvi, I., Baron-Lühr, B., Gerdes, J., & Hasan, T. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1190 · Cited by 78
Self-citationCelli, J. P., Rizvi, I., Evans, C. L., Abu-Yousif, A. O., & Hasan, T. (2010) · Journal of Biomedical Optics · doi:10.1117/1.3483903 · Cited by 75 · cited 6×
“The protocols for nonflow 3D ovarian cancer cultures were based on previously published methods developed by us and others (51, 53, 55, 57, 59, 60, 75, 76).”
MethodInfluentialSelf-citationPATHOGENESIS OF ASCITES IN PERITONEAL CARCINOMATOSIS1
Holm-Nielsen, P. (1953) · Acta Pathologica Microbiologica Scandinavica · doi:10.1111/j.1699-0463.1953.tb04805.x · Cited by 68
Cheng, J.-C., Auersperg, N., & Leung, P. C. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034071 · Cited by 66
Selective removal of ovarian cancer cells from human ascites fluid using magnetic nanoparticles
Scarberry, K. E., Dickerson, E. B., Zhang, Z. J., Benigno, B. B., & McDonald, J. F. (2009) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2009.11.003 · Cited by 66 · cited 2×
“3B), we chose cell concentrations that span three orders of magnitude (10(4), 10(5), and 10(6) cells/mL) to account for a broad range of possibly relevant seeding densities (12, 66).”
BackgroundTargeting the EGF Receptor for Ovarian Cancer Therapy
Zeineldin, R., Muller, C. Y., Stack, M. S., & Hudson, L. G. (2009) · Journal of Oncology · doi:10.1155/2010/414676 · Cited by 60 · cited 2×
“Several studies have identified the EGFR as an independent prognostic indicator for poor outcomes (20, 80), although the clinical consequences of EGFR expression remain controversial (23, 24, 81).”
BackgroundFéki, A., Berardi, P., Bellingan, G. J., Major, A. L., Krause, K., Petignat, P., Zehra, R., Pervaiz, S., & Irminger‐Finger, I. (2009) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.12.003 · Cited by 59
Intraperitoneal Photodynamic Therapy
Cengel, K. A., GLATSTEIN, E. J., & Hahn, S. M. (2007) · Springer eBooks · doi:10.1007/978-0-387-48993-3_34 · Cited by 58 · cited 1×
“A biophysical cytotoxic therapy that involves the light-based activation of a photosensitive molecule, PDT has demonstrated clinical promise for the treatment of peritoneal cancers, particularly ovarian carcinoma (90, 91).”
BackgroundHo, C.-M., Chang, S.-F., Hsiao, C.-C., Chien, T.-Y., & Shih, D. T.-B. (2012) · Journal of Biomedical Science · doi:10.1186/1423-0127-19-23 · Cited by 58
Integrin Inhibitors as a Therapeutic Agent for Ovarian Cancer
Sawada, K., Ohyagi-Hara, C., Kimura, T., & Morishige, K. (2011) · Journal of Oncology · doi:10.1155/2012/915140 · Cited by 54 · cited 1×
“The flow-induced decrease in E-cadherin expression concomitant with no change in integrin α5, observed in this study, is consistent with an expression profile that promotes metastases in ovarian cancer (8, 84, 85).”
BackgroundElie, C., Geay, J.-F., Morcos, M., Tourneau, A. L., Girre, V., Broët, P., Marmey, B., Chauvenet, L., Audouin, J., Pujade-Lauraine, É., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601961 · Cited by 53
Galaz, S., Espada, J., STOCKERT, J. C., Pacheco, M., Sanz-Rodrı́guez, F., Arranz, R., Rello‐Varona, S., Cañete, M., Villanueva, Á., Esteller, M., et al. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20374 · Cited by 51 · cited 1×
“The flow-induced decrease in E-cadherin expression concomitant with no change in integrin α5, observed in this study, is consistent with an expression profile that promotes metastases in ovarian cancer (8, 84, 85).”
BackgroundCytology, immunopathology and flow cytometry in the diagnosis of pleural and peritoneal effusions.
Croonen, A., van der Valk, P., Herman, C. J., & Lindeman, J. (1988) · PubMed · Cited by 46
Integrin-Mediated Adhesion and Signalling in Ovarian Cancer Cells
Buczek‐Thomas, J. A., Chen, N., & Hasan, T. G. (1998) · Cellular Signalling · doi:10.1016/s0898-6568(97)00074-0 · Cited by 35
Self-citationPuraMatrix Encapsulation of Cancer Cells
Abu‐Yousif, A. O., Rizvi, I., Evans, C. L., Celli, J. P., & Hasan, T. G. (2009) · Journal of Visualized Experiments · doi:10.3791/1692 · Cited by 31
Self-citationJungmann, O., Nikolovska, K., Stock, C. M., Schulz, J.-N., Eckes, B., Riethmüller, C., Owens, R. T., Iozzo, R. V., & Seidler, D. G. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050809 · Cited by 27
Dimou, A., Agarwal, S., Anagnostou, V., Viray, H., Christensen, S. M., Rothberg, B. G., Zolota, V., Syrigos, K., & Rimm, D. L. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2011.04.031 · Cited by 23 · cited 1×
“The EGFR may also be an important negative prognostic indicator of disease-free survival and overall survival, depending in part on the stage of the disease and the technique used to evaluate expression of this biomarker (20, 25).”
MethodA phase II study of ixabepilone (BMS-247550) in metastatic renal-cell carcinoma
Posadas, E. M., Undevia, S. D., Manchen, E., Wade, J. L., Colevas, A. D., Karrison, T. G., Vokes, E. E., & Stadler, W. M. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.4.3831 · Cited by 23 · cited 1×
“Nonetheless, the EGFR remains an important and relevant focus for molecularly targeted therapies, as evidenced by recent clinical trials (23, 80, 82, 83).”
BackgroundKenny, P. A., Lee, G. Y., Myers, C. A., Neve, R. M., Semeiks, J. R., Spellman, P. T., Lorenz, K., Lee, E. H., Barcellos-Hoff, M. H., Petersen, O. W., et al. (2007) · Molecular Oncology · doi:10.1016/j.molonc.2007.02.004 · Cited by 2
Research works printed but not linked: 4
- 10.1016/j.cell.2006.11.001 · DOI · Paper page
- 10.1016/s1470-2045(06)70939-1 · DOI · Paper page
- 10.1158/1078-0432.ccr-05-1436 · DOI · Paper page
- 10.2174/156800910791190175 · DOI · Paper page
Cited by
Organs-on-chips: into the next decade
Low, L. A., Mummery, C., Berridge, B. R., Austin, C. P., & Tagle, D. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0079-3 · Cited by 1,029
Modelling cancer in microfluidic human organs-on-chips
Sontheimer-Phelps, A., Hassell, B. A., & Ingber, D. E. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-018-0104-6 · Cited by 906
Ahmed, N., & Stenvers, K. L. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00256 · Cited by 482
“These studies can be performed using microfluidic systems to investigate the impact of ascites on resident and non-resident cell systems either individually or in combination (20).”
BackgroundInfluentialFluids and their mechanics in tumour transit: shaping metastasis
Follain, G., Herrmann, D., Harlepp, S., Hyenne, V., Osmani, N., Warren, S. C., Timpson, P., & Goetz, J. G. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0221-x · Cited by 412
Advances in Plasmonic Technologies for Point of Care Applications
Tokel, O., Inci, F., & Demirci, U. (2014) · Chemical Reviews · doi:10.1021/cr4000623 · Cited by 407
Self-citation
Metadata
- Authors
- Rizvi, I., Gurkan, U. A., Tasoglu, S., Alagic, N., Celli, J. P., Mensah, L. B., Mai, Z., Demirci, U., & Hasan, T.
- Affiliations
- Harvard University (US)
- Brigham and Women's Hospital (US)
- Bio-Acoustic-Microelectromechanical Systems in Medicine Laboratory, Divisions of Biomedical Engineering and Infectious Diseases, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA 02139;
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2013-05-03
- Volume
- 110
- Issue
- 22
- Pages
- E1974-83
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3670329
- OpenAlex
- W2069579706
- Cited by
- 234
- References
- 98
- Citations by year
- 2026: 7 · 2025: 9 · 2024: 30 · 2023: 21 · 2022: 28 · 2021: 21 · 2020: 22 · 2019: 21 · 2018: 14 · 2017: 13 · 2016: 14 · 2015: 13 · 2014: 14 · 2013: 7
- FWCI
- 8.57
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- Funders
- National Heart, Lung, and Blood Institute (R21HL112114)
- National Cancer Institute (R01CA158415, P01CA084203, R01CA160998, K99CA155045)
- National Institute of Allergy and Infectious Diseases (R01AI081534, R21AI087107)
- National Institute of Biomedical Imaging and Bioengineering (R01EB015776)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular Mechanics and Interactions
- Keywords
- epithelial-mesenchymal transition, ovarian cancer, laminar flow, hydrodynamic forces, metastasis, EGF receptor, E-cadherin, vimentin, tumor heterogeneity, biomarker expression, peritoneal carcinomatosis, ascites
- MeSH terms
- Ascites, Female, Humans, Models, Biological, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Peritoneal Neoplasms, Biomarkers, Tumor, Cadherins, Gene Expression Regulation, Neoplastic, Cell Culture Techniques, Microfluidic Analytical Techniques, Epithelial-Mesenchymal Transition, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.